Adaptive Biotechnologies has signed a $300 million collaborative licensing agreement with Genentech to develop highly personalized cancer therapies. In addition… Read More
Seattle-based biotech company PhaseRx develops drug candidates to treat rare, often life-threatening liver diseases, and one of their candidates just got… Read More